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We analyzed dengue virus-specific CD4+ CD8- cytotoxic T lymphocytes (CTL) at the clonal level to further
understand their role in dengue virus infections. Stimulation of peripheral blood mononuclear cells from two
dengue virus type 4 (D4V)-immune donors with live D4V or noninfectious D4V antigen generated 17 HLA class
11-restricted CD4+ CTL capable of specific lysis of dengue virus antigen-treated autologous lymphoblastoid cell
lines. Thirteen clones were D4V specific, three clones were cross-reactive for D2V and D4V, and one clone was
cross-reactive for D1V, D3V, and D4V. Antigen recognition by six D4V-specific clones and three D2V- and
D4V-cross-reactive clones was restricted by HLA-DR7. Five D4V-specific CD4+ CTL clones lysed autologous
lymphoblastoid cell lines infected with a dengue virus-vaccinia virus recombinant containing the E gene of
D4V, whereas three serotype-cross-reactive CTL clones did not. These results indicate that E-specific clones are
serotype specific and HLA-DR7 restricted in these two donors and suggest that a common epitope on E protein
may be recognized. E protein-specific CD4+ CTL may be important mediators of virus clearance especially
during reinfection with the same serotype as that in primary infection by providing help for virus-specific
antibody production and lysis of virus-infected cells.
Dengue is a viral illness that causes extensive morbidity
throughout epidemic tropical areas of the world and is a
significant cause of mortality in Southeast Asia (9). Dengue
viruses are mosquito-borne flaviviruses which have been sub-
grouped into four antigenically related serotypes, dengue virus
types 1, 2, 3, and 4 (DIV, D2V, D3V, and D4V, respectively)
(14). Dengue virus infections may be asymptomatic, cause a
self-limited febrile illness known as dengue fever, or, in a small
percentage of cases, cause a severe illness known as dengue
hemorrhagic fever (DHF) (8). Epidemiological studies have
shown that the incidence ofDHF is much greater in individuals
experiencing secondary infections with a serotype of dengue
virus distinct from the virus serotype that caused the primary
infection (8).
Primary infection with a dengue virus appears to confer
lifelong protection against reinfection with a dengue virus of
the same serotype (32). Presumably, this protection is gener-
ated through production of virus-specific neutralizing antibod-
ies and also possibly by serotype-specific memory CD4+ and
CD8+ T cells. When secondary infections with homotypic virus
occur in the absence of sufficient levels of specific neutralizing
antibodies, the infecting virus will multiply at the site of entry,
anamnestic immune responses will be induced, and virus will
be cleared. However, during secondary infection with a sero-
type different from that which caused primary infection, there
is increased risk for more severe disease (8, 10).
Virus-specific antibody responses require help from CD4+ T
lymphocytes. The presence of an early serotype-cross-reactive
immunoglobulin G (IgG) response to secondary dengue virus
infection predicts the existence of serotype-cross-reactive
memory CD4+ T lymphocytes (8, 11). We have previously
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reported the characterization of dengue virus-specific, sero-
type-cross-reactive CD4+ and CD8+ human T lymphocytes
which predominantly recognize nonstructural proteins (18, 22,
24). To date, structural protein-specific, serotype cross-reactive
human CD4+ T lymphocytes have not been reported.
Serotype-specific CD4+ T lymphocytes may play an impor-
tant role in protective immunity against reinfection with the
same serotype of dengue virus. In this paper, we describe the
isolation and characterization of D4V-specific CD4+ cytotoxic
T-lymphocyte (CTL) clones generated from two donors. Most
of these D4V-specific clones recognize envelope (E) protein,
while none of the serotype-cross-reactive clones recognize E
protein. E protein contains epitopes recognized by serotype-
specific neutralizing antibodies (7, 13). The presence of sero-
type-specific CD4+ T-cell epitope(s) on E protein suggests that
T-cell immune responses to E protein may contribute to
protection against reinfection with the homologous serotype of
dengue viruses.
MATERIALS AND METHODS
Flaviviruses. DIV (Hawaii strain), D2V (New Guinea C
strain), D3V (CH53489 strain), D4V (814669 strain), yellow
fever virus (17D strain), and West Nile virus (ElOl strain) were
used in this study.
These viruses were propagated in C6/36 mosquito cells as
previously described (20). Briefly, C6/36 cell monolayers were
infected at a multiplicity of infection of 0.1 PFU per cell and
were incubated for 7 days at 28°C in minimal essential medium
containing 2% fetal calf serum (FCS) and 0.8% bovine serum
albumin, and the supernatant was collected and stored at
- 70°C. Viral titers of supernatants were estimated to be 107 to
108 PFU/ml by plaque assays on Vero cell monolayers.
Preparation of noninfectious flavivirus antigens. D1V,
D2V, D3V, D4V, yellow fever virus, and West Nile virus
antigens were prepared from infected Vero cell monolayers as
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previously described (22). Briefly, Vero cell monolayers were
infected at a multiplicity of infection of 1 PFU per cell and
were incubated at 37°C in minimal essential medium supple-
mented with 25 mM HEPES (N-2-hydroxyethylpiperazine-N'-
2-ethanesulfonic acid)-2 mM glutamine-100 U of penicillin
per ml-100 pLg of streptomycin per ml containing 2% FCS until
50% of the cells displayed cytopathic effects. Cells were then
harvested by scraping, washed, fixed with 0.025% glutaralde-
hyde in phosphate-buffered saline (PBS) for 15 min on ice,
washed again, and resuspended at 3 x 108 cells per ml in
RPMI. The suspension of fixed cells was then sonicated on ice
with a sonic dismembrator (Fisher Chemical Co., Pittsburgh,
Pa.) for 3 min and was centrifuged at 1,600 x g for 10 min at
4°C. The supernatant was collected, aliquoted, and frozen at
- 70°C as viral antigen. Control antigen from uninfected Vero
cell monolayers was prepared similarly.
DV-W. Recombinant dengue-vaccinia viruses (DV-VV)
were constructed by insertion of dengue viral genome seg-
ments from D4V (814669 strain) into the pSC11 vaccinia virus
vector under control of the vaccinia virus P7.5 early-late
promoter as previously described (2, 31, 34).
PBMC. Human peripheral blood mononuclear cells
(PBMC) were obtained from two healthy donors, donors 1 and
2, who had been immunized with the D4V strain 814669 as a
candidate live vaccine 1 year earlier (15). The sera of donors 1
and 2 did not contain antibody to dengue viruses before
immunization. Donor 1 did not have any significant clinical
symptoms; however, viremia was detected on day 9, and donor
1 developed D4V-specific neutralizing antibodies with a titer
of 1:90 on day 30 after immunization. Donor 2 did not develop
any significant clinical symptoms; however, viremia was de-
tected on days 12 to 15, and donor 2 developed D4V-specific
neutralizing antibodies with a titer of 1:30 on day 30 after
immunization. PBMC were collected by leukopheresis 1 year
after immunization and were isolated by Ficoll-Hypaque den-
sity gradient centrifugation. These PBMC were then resus-
pended in RPMI containing 20% FCS and 10% dimethyl
sulfoxide and were frozen in a programmable cryopreservation
chamber (CRYO-MED, Mt. Clemens, Mich.). The HLA alle-
les of donor 1 were A2, A23, B35, Cw4, DR7, DRw53, and
DQw2, and those of donor 2 were A2, A28, B51, Bw57, Cw6,
DR5, DR7, DRw52, DRw53, DQwl, and DQw2.
Establishment of dengue virus-specific T-cell clones. PBMC
from donor 1 were suspended at 4 x 106 cells per ml in RPMI
containing 20% heat-inactivated human AB serum (HABS;
Hazelton Research Products, Inc., Lenexa, Kans.). A 1.0-ml
volume of cell suspension was added to 1.0 ml of D4V in
24-well cluster plates (Costar, Cambridge, Mass.), as previ-
ously described (3). Dengue virus-specific, class II-restricted
CTL clones were propagated from limiting dilutions of bulk
cultures on day 9 at 10 to 100 cells per well. Limiting-dilution
cultures were set up in 96-well round-bottom plates (Costar)
with each well containing 100 ,lI of AIM-V medium containing
20% HABS (Advanced Biotechnologies, Inc., Columbia, Md.),
20% TCGF, and 105 gamma-irradiated autologous PBMC and
100 ,ul of D4V. Wells demonstrating sufficient growth and cell
density at each 7-day period were restimulated in 48-well
plates with 0.5 ml of AIM-V medium containing 20% HABS,
20% TCGF, and 106 gamma-irradiated autologous PBMC and
0.5 ml of D4V. On day 3 postrestimulation, 48-well plates were
fed with 0.5 ml of AIM-V containing 20% HABS, 20% TCGF,
and 10 U of recombinant human interleukin-2. Limiting-
dilution culture of 192 seeded wells produced 22 clones which
grew in 48-well plates. A total of 21 clones were determined to
be CD3+ CD4+ CD8- by fluorescence microscopy analyses.
CD4+ CTL clones were similarly established from PBMC of
donor 2 by using noninfectious D4V antigen instead of live
D4V as previously described (24). Two clones were established
from a 96-well limiting-dilution culture at 1 cell per well.
Phenotypic analysis. CTL clones were washed twice in cold
PBS. Fluorescein isothiocyanate-conjugated antibodies (Lee
Biomolecular, San Diego, Calif.) were added to 105 cells at a
final dilution of 1:20. Conjugated antibodies used were anti-
Leu2 (anti-CD8), anti-Leu3 (anti-CD4), and anti-Leu4 (anti-
CD3). Control cells were labeled with conjugated normal
mouse IgG. Labeled CTL were then washed three times in
ice-cold PBS, and surface expression of CD3, CD4, and CD8
was qualitatively analyzed by fluorescence microscopy.
Preparation of target cells. Autologous B lymphoblastoid
cell lines (LCL) were derived through transformation of
peripheral blood lymphocytes with Epstein-Barr virus as pre-
viously described (18) and were maintained in RPMI contain-
ing 10% FCS at 37°C. Culture fluid of Epstein-Barr virus-
transformed marmoset cell line B95-8 was used as a source of
Epstein-Barr virus.
Antigen-treated LCL target cells were prepared by seeding 2
x 105 cells per well in 24-well cluster plates in a final volume
of 0.5 ml of RPMI containing 10% FCS and dengue virus
antigen diluted 1:50 to 1:75. Cells were incubated for 16 h with
antigen. DV-VV-infected target cells were prepared by infect-
ing 106 LCL with DV-VV at a multiplicity of infection of
approximately 20 PFU per cell for 2 h. After being washed
twice, LCL were cultured in RPMI containing 10% FCS at
37°C for 16 to 20 h and were used as target cells.
Target cells were washed twice in RPMI containing 10%
FCS and were labeled by incubation with 0.25 mCi Na2 'CrO4
(New England Nuclear Research Products, Boston, Mass.) for
45 to 60 min in 100 [L at 37°C. After four washes to remove
excess 5"Cr, target cells were counted and resuspended at 104
cells per ml for use in cytotoxicity assays.
Cytotoxicity assays. Cytotoxicity assays were performed in
96-well round-bottom plates to which 103 labeled targets were
added in 100 [lI of RPMI containing 10% FCS. A 100-,ul
volume of effector cells in RPMI containing 10% FCS was
subsequently added. All assays were performed in triplicate or
quadruplicate. Following centrifugation at 200 x g for 5 min,
the plates were incubated at 37°C for 5 h. Supernatant fluids
were harvested, and 51Cr content was measured in a gamma
counter (Packard, Sterling, Calif.). The percent specific release
was calculated as (cpm experimental release - cpm sponta-
neous release)/(cpm maximal release - cpm spontaneous
release) x 100, where cpm is counts per minute.
RESULTS
Establishment of D4V-specific CD4+ CTL clones. Fifteen
CD4+ CD8 - T-cell clones and two CD4+ CD8 - CTL clones
were established from PBMC of the D4V-immune donors 1
and 2, respectively, as described in Materials and Methods.
Twelve of the 15 CD4+ CTL clones derived from donor 1 were
specific for D4V, and 3 clones were cross-reactive for D2V and
D4V. One of the two CD4+ CTL clones derived from PBMC
of donor 2 was specific for D4V, and one clone was cross-
reactive for D1V, D3V, and D4V. Table 1 presents data on the
D4V-specific and serotype-cross-reactive lysis of target cells by
10 representative CD4+ CD8- CTL clones. None of these
clones recognized yellow fever virus or West Nile virus, which
are related flaviviruses (data not presented).
HLA-DR7-restricted recognition of D4V by CD4+ CTL
clones. The HLA class II alleles of donor 1 and donor 2 were
DR7, DQw2, and DRw53 and DR5, DR7, DQw2, DQw3,
DRw52, and DRw53, respectively. The HLA restriction of nine
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TABLE 1. Dengue virus serotype specificities of CD4+ CD8- T-cell clones established from donors I and 2"
% Specific 51Cr release'
Clone' Control
DIV D2V D3V D4V antigen
Serotype specific
CB6.1 24 10 12 67 16
CB6.3 1 0 0 70 0
CB6.15 0 2 0 75 3
CB6.21 0 10 0 54 0
CB6.22 2 5 0 80 1
CP5 0 0 0 65 0
Serotype cross-reactive
CB6.18 7 51 0 16 5
CB6.19 1 38 0 22 1
CB6.20 9 62 0 22 0
CP3 31 0 44 33 0
"A total of 103 target cells were incubated with effector cells for 5 h at an effector/target ratio of 10:1.
"Clones CB6. 1, CB6.3, CB6.15, CB6.21, CB6.22, CB6.18, CB6.19, and CB6.20 were established from the PBMC of donor 1, and clones CP3 and CP5 were established
from the PBMC of donor 2.
' The percentage of specific 5'Cr release was calculated by the formula described in Materials and Methods.
dengue virus-specific CTL clones was determined in cytotox-
icity assays with HLA class TI-defined allogeneic LCL as target
cells. All of the CD4+ CTL clones which originated from
donor 1, including the five D4V-specific clones and three
clones cross-reactive for D2V and D4V, lysed dengue antigen-
treated allogeneic target cells which shared HLA-DR7 (Table
2). A clone CP5 derived from donor 2 also lysed dengue virus
antigen-cultured allogeneic target cells which shared HLA-
DR7 (Table 3). These results indicate that all of these nine
CD4+ CTL clones were HLA-DR7 restricted.
Recognition of E protein by D4V-specific CD4+ CTL clones.
The dengue virus protein specificities of these dengue virus-
specific CD4+ CTL clones were examined by using recombi-
nant vaccinia viruses which contain genome coding for proteins
of D4V or D2V. Five D4V-specific clones, CB6. 1, CB6.3,
CB6.15, CB6.21, and CP5, lysed target cells infected with
recombinant vaccinia virus which expressed the E protein of
D4V but did not lyse target cells infected with recombinant
vaccinia viruses which expressed the NS3 protein of D4V; NS1
and NS2a of D4V; or C, pre-M, and E proteins of D2V (Table
TABLE 2. HLA-DR7-restricted recognition of D4V antigen by CD4+ CTL clones established from donor 1
% Specific 5'Cr release'
Expt and target Shared HLA class I D4V specific clones D2V- and D4V cross-reactive clones
cell7 allele(s) D4V__________clones_D2V-_and_D4V__r_____________ clones
CB6.1 CB6.3 CB6.15 CB6.21 CB6.22 CB6.18 CB6.19 CB6.20
Expt 1
Autologous DR7, DQw2, DRw53 24 28 59 27 46 45 57 58
CP DR7, DQw2, DRw53 15 22 30 12 37 21 39 48
9049 DR7, DQw2, DRw53 42 45 47 43 55 NDd ND ND
PG DQw2 0 1 3 3 0 0 0 0
FE DQw2 0 0 3 2 0 0 1 1
9038 None 0 0 0 ND 0 1 2 2
Expt 2
Autologous DR7, DQw2, DRw53 21 ND 31 15 35 27 28 38
9052 DR7, DRw53 28 ND 49 17 57 31 35 44
VAVY DQw2 0 ND 0 0 0 0 1 2
Expt 3
Autologous DR7, DQw2, DRw53 59 62 68 72 75 32 40 51
9049 DR7, DQw2, DRw53 ND ND ND ND ND 25 30 34
9087 DQw2 ND ND ND ND ND 0 0 0
JC DRw53 0 1 2 4 1 3 0 0
MS DRw53 0 0 0 8 4 ND ND ND
9029 DRw53 ND ND ND ND ND 2 0 0
"A total of 103 target cells were incubated with effector cells for 5 h.
"D4V antigen-treated target cells were used for D4V-specific clones CB6.1, CB6.3, CB6.15, CB6.21, and CB6.22, and D2V antigen-treated target cells were used
for D2V- and D4V-cross-reactive clones CB6.18, CB6.19, and CB6.20.
' The effector/target ratios were 7:1 for CB6.1, CB6.15, CB6.22, and CB6.18; 8:1 for CB6.19; 10:1 for CB6.3; 12:1 for CB6.20; and 18:1 for CB6.21 in experiment 1;
10:1 for CB6.1, CB6.15, CB6.21, and CB6.22; and 20:1 for CB6.18, CB6.19, and CB6.20 in experiment 2; 6:1 for CB6.15; 9:1 for CB6.22; 11:1 for CB6.3; 13:1 for CB6.1;
14:1 for CB6.19; 15:1 for CB6.20; and 20:1 for CB6.21 and CB6.19.
" ND, no data.
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TABLE 3. HLA-DR7-restricted recognition of D4V antigen by a
CD4+ CTL clone (CP5) established from donor 2T




Autologous DR5, DR7, DQw2, DQw3, DRw52, 26
DRw53
CB DR7, DQw2, DRw53 50
9049 DR7, DQw2, DRw53 53
PG DR5, DQw2, DQw3 0
FE DR5, DQw2, DQw3 0
9038 DQw3 (DQ7) 0
Expt 2
Autologous DR5, DR7, DQw2, DQw3, DRw52, 92
DRw53
9052 DR7, DQw3 (DQ9), DRw53 68
VAVY DQw2, DRw52 0
Expt 3
Autologous DR5, DR7, DQw2, DQw3, DRw52, 82
DRw53
JC DQw3, DRw53 0
MS DQw3, DRw53 0
Expt 4
Autologous DR5, DR7, DQw2, DQw3, DRw52, 54
DRw53
CB DR7, DQw2, DRw53 90
TB DR5, DQw2 4
All DQw2 0
A2 DQw3 2
a A total of 103 D4V antigen-treated target cells were incubated with effector
cells for 5 h.
b The effector/target ratios were 9:1 in experiment 1, 10:1 in experiment 2, and
15:1 in experiments 3 and 4.
4). One D4V-specific clone, CB6.22, and three D2V- and
D4V-cross-reactive clones, CB6.18, CB6.19, and CB6.20, did
not lyse target cells infected with any of the tested recombinant
vaccinia viruses, implying that these clones recognized epitopes
not represented in these recombinant constructs.
DISCUSSION
In this paper, we characterized a panel of E protein-specific
human CD4+ CD8 - CTL clones. E protein was recognized by
human CD4+ CTL clones derived from two D4V-immune
individuals. All CD4+ CTL clones which recognized E protein
were D4V specific and HLA-DR7 restricted. This is the first
demonstration of the presence of human CD4+ T-cell
epitope(s) on dengue virus E protein, although the epitopes on
E protein recognized by murine helper T cells have been
reported by other investigators (25, 28, 30).
These serotype-specific CD4+ T cells may play an important
role in protection against secondary infections with a dengue
virus of the same serotype. In the absence of complete
neutralization of challenge virus in secondary infections, it is
probable that monocytes and activated lymphocytes will be
infected by homologous dengue virus. These infected cells that
express high levels of HLA class II need to be eliminated by
dengue virus-specific CD4+ and CD8+ CTLs. We have previ-
ously reported the existence of E protein-specific CD8+ CTLs
in donor 1 (3). Interleukin-2-producing CD4+ CTLs may be
instrumental in enhancing clonal expansion of dengue virus-
specific CD8+ CTLs. In addition, E protein-specific CD4+ T
lymphocytes provide help necessary for anamnestic neutraliz-
ing antibody responses which are predominantly E protein
specific (4, 7, 13). Passive transfer of neutralizing antibody can
protect mice from lethal infection with dengue viruses (17).
Therefore, serotype-specific CD4+ CTLs in conjunction with
neutralizing antibody probably mediate the long-term protec-
TABLE 4. Recognition of E protein by D4V-specific CD4+ CTL clones"
Expt and antigen with % specific 5"Cr release'
which autologous LCL D4V specific clones D2V- and D4V-cross-reactive clones
were infected or
cultured" CB6.1 CB6.3 CB6.15 CB6.21 CB6.22 CP5 CB6.18 CB6.19 CB6.20
Expt 1
VV(D4:E) 38 21 NDd 43 14 69 8 7 5
VV(D4:NS3) 0 1 ND 0 3 4 2 3 0
VV(D2:C-PrM-E) 0 0 ND 0 0 ND 0 0 0
VV(control) 0 5 ND 4 5 11 2 4 1
D4V antigen 58 ND ND 54 85 36 37 40 44
D2V antigen 0 ND ND 7 7 ND 27 35 41
None 2 ND ND 2 5 0 7 2 1
Expt 2
VV(D4:E) 85 85 75 85 ND ND ND ND ND
VV(D4:NS1-NS2a) 0 0 0 0 ND ND ND ND ND
VV(control) 13 3 7 0 ND ND ND ND ND
Expt 3
VV(D4:E) 30 14 ND 54 11 50 6 8 7
VV(D4:NS3) 0 0 ND 0 0 5 7 2 0
VV(control) 2 2 ND 2 7 1 6 5 6
D4V antigen 41 ND ND 48 68 71 21 28 34
None 2 ND ND 2 5 0 3 3 0
"
A total of 103 target cells were incubated with effector cells for 5 h.
b VV(D4:E), recombinant vaccinia virus which contains genes coding for E protein of D4V; VV(D4:NS3), recombinant vaccinia virus which contains genes coding
for NS3 protein of D4V; VV(D2:C-PrM-E), recombinant vaccinia virus which contains genes coding for C, PrM, and E proteins of D2V; VV(D4:NS1-NS2a),
recombinant vaccinia virus which contains genes coding for NS1 and NS2a proteins of D4V.
cThe effector/target ratios were 7:1 for CP3; and 20:1 for CB6.1, CB6.3, CB6.21, CB6.22, CB6.18, CB6.19, and CB6.20 in experiment 1; 10:1 for CB6.1, CB6.3,
CB6.15, and CB6.21 in experiment 2; and 6:1 for CP3 and 20:1 for CB6.1, CB6.3, CB6.21, CB6.22, CB6.18, CB6.19, and CB6.20 in experiment 3.
"ND, no data.
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tive immunity against challenge with a homologous serotype of
virus.
The observation that most of the serotype-specific CD4+
CTL clones established from these donors recognize epitopes
on E protein is of great interest. E protein is a 56- to 57-kDa
glycosylated protein with 60 to 70% conservation of amino acid
sequence homology among the four serotypes (6, 14, 16). E
protein of strains within each serotype share more than 95%
sequence homology (6, 16). In contrast, there is an approxi-
mately 75% sequence homology among the more highly con-
served nonstructural proteins NS3 and NS5 (16). We previ-
ously described serotype-cross-reactive CD4+ CTL clones that
recognize NS3 protein (18). The relative lack of serotype-
cross-reactive, E protein-specific CTL clones isolated from
donors 1 and 2 may be secondary to the decreased amino acid
conservation among E proteins compared with that of non-
structural proteins. Furthermore, there is compelling evidence
that virus-specific memory B cells selectively present antigenic
peptides to T cells (5, 26, 27). The recognition sites of B cells
and CD4+ T cells are topographically linked on influenza virus
hemagglutinin (1, 33). Immunization of mice with dengue virus
synthetic peptides induced virus-specific or peptide-specific
IgG antibodies, suggesting the presence of a B-cell and helper
T-cell epitope on one peptide (28, 30). Both the IgG response
and the T-cell response to primary dengue virus infection are
predominantly serotype specific, with lower levels of serotype
cross-reactivity present (8, 24). Serotype-specific, E protein-
specific B cells likely favor selection of serotype-specific, E
protein-specific memory CD4+ T cells.
DHF usually occurs during secondary infections with a
serotype of dengue virus different from the virus which caused
the primary infection (8). We have previously shown that
soluble CD4 is significantly increased in the sera of children
with DHF relative to children with uncomplicated dengue
fever (21). Our group has hypothesized that DHF may be
triggered by brisk stimulation of serotype cross-reactive mem-
ory T cells and the massive production and release of vasoac-
tive cytokines (19). One source of vasoactive cytokines may be
infected monocytes which are lysed by cytotoxic T lympho-
cytes. Monocytes could be targeted for lysis by E protein-
specific CD4+ CTL clones through Fc receptor internalization
of antibody-bound envelope proteins (23). Evidence for virus-
specific CD4+ CTL clones in a widening range of human and
primate virus infections continues to accumulate. Recently,
Hammond et al. compared the CD4+ versus CD8+ gpl60-
specific CTL clones in human immunodeficiency virus type 1
vaccine recipients (12). A role for CD4+ CTL-mediated im-
munopathology secondary to lysis of uninfected CD4 cells
which process free gpl6O bound to CD4 receptors was sug-
gested. Penna et al. demonstrated that hepatitis B virus-
specific CD4+ CTL clones efficiently lysed autologous HLA
class TI-positive cells expressing endogenously synthesized
envelope antigens (29). Five of our dengue virus serotype-
specific CD4+ CTL clones efficiently lysed autologous HLA
class II-positive LCL infected with DV-VV expressing D4V E
protein. No serotype-cross-reactive clones lysed LCL infected
with DV-VV expressing D4V E protein or D2V structural
proteins despite efficient lysis of dengue virus antigen-treated
LCL. These data suggest that serotype-cross-reactive CTL
clones CB6.18, CB6.19, and CB6.20 recognize epitopes on
nonstructural proteins not represented by our DV-VV con-
structs.
All of the CD4+ CTL clones that we isolate from donors 1
and 2 examined were HLA-DR7 restricted. E protein-specific,
HLA-DR7-restricted CD4+ CTL clones from donor 1 may
recognize the same epitope on E protein, which may be
identical to or different from the epitope recognized by donor
2. Other HLA haplotypes may favor expansion of other CTL
subsets, including serotype-cross-reactive, E protein-specific
CD4+ CTL clones. We plan to define the epitope(s) on E
protein at the amino acid level using recombinant vaccinia
viruses containing truncated D4V E protein genes, as well as
synthetic peptides. Identification of epitopes recognized by
CD4+ CTL clones from these and other donors should provide
important insights for understanding human T-cell responses
to dengue viruses and the pathogenesis of DHF.
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